Conclusions
The agonist-antagonists are effective analgesics with some significant differences from the pure agonists. The clinical indications for these two classes overlap but are not identical. All of the agonist-antagonists have excellent safety profiles: life-threatening respiratory depression is uncommon, and minor toxic effects like nausea, constipation, and urinary retention occur less frequently than with morphine. Several of these agents have been widely available for over ten years, and during that time they have been subject to remarkably little diversion or abuse.
There are at least three promising applications for these drugs in anaesthesia:
-
1
The kappa type drugs appear to be useful as sedatives and adjuncts to local or regional anaesthesia. We need better dosage guidelines for this indication and more data on interactions with other sedative drugs like benzodiazepines.
-
2
Epidural butorphanol has already shown some promise in obstetrics. A single dose provides relief of post-Caesarean pain for six to ten hours without pruritus or excessive sedation.
-
3
Finally, these analgesics may have advantages for Patient Controlled Analgesia, since they do not require locked pumps or narcotic inventory control. If the use of agonist-antagonists can significantly reduce pharmacy paperwork, their total costs will probably compare favourably with morphine and meperidine.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Lasagna L, Beecher HK. The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man. J Pharmacol Exp Ther 1954; 112: 356–363.
Wilder A, Fraser HF, Isbell H. N-allylnormorphine: effects of single doses and precipitation of acute “abstinence syndromes” during addiction to morphine, methadone or heroin in man (postaddicts). J Pharmacol Exp Ther 1953; 109: 8–20.
Keats AS, Telford J. Studies of analgesic drugs. X. Respiratory effects of narcotic antagonists. J Pharmacol Exp Ther 1966; 151: 126–32.
Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine-and nalorphinelike drugs in the non-dependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197: 517–32.
Houde RW, Wallenstein SL. Clinical studies of moiphinenalorphine combination. Fed Proc 1956; 15: 440–1.
Abboud TK, Moore M, Zhu J, et al. Epidural butorphanol or morphine for the relief of post-cesarean section pain: ventilatory responses to carbon dioxide. Anesth Analg 1987; 66: 887–93.
Stanley TH, Reddy P, Gilmore S, Bennett G. The cardiovascular effects of high-dose butorphanol-nitrous oxide anaesthesia before and during operation. Can Anesth Soc J 1983; 30: 337–41.
Murphy MR, Hug CC. The enflurane sparing effect of morphine, butorphanol and nalbuphine. Anesthesiology 1982; 57: 489–92.
Houde RW. Analgesic effectiveness of the narcotic agonist-antagonists. Br J Clin Pharmacol 1979; 7: 297S-308S.
Kaiko RF, Wallenstein SL, Rogers AG, Canel A, Jacobs B, Houde RW. Intramuscular meptazinol and morphine in postoperative pain. Clin Pharmacol Ther 1985; 37: 589–96.
Bacon BR, Marshall JB. Randomized, prospective, double-blind clinical trial of butorphanol and diazepam in patients undergoing upper gastrointestinal endoscopy. Acute Care 1988; 12(Suppl 1): 57–62.
Nagashima H, Karamanian A, Malovany R, et al. Respiratory and circulatory effects of intravenous butorphanol and morphine. Clin Pharmacol Ther 1976; 19: 738–45.
Gal TJ, Di Fazio CA, Moscicki J. Analgesic and respiratory depressant activity of nalbuphine: a comparison with morphine. Anesthesiology 1982; 57: 367–74.
Heel RC, Brogden RN, Speight TM, Avery GS. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 1979; 17: 81–110.
Mails JL, Rosenthale ME, Gluckman MI. Animal pharmacology of WY-16225, a new analgesic agent. J Pharmacol Exp Ther 1975; 194: 488–98.
Radnay PA, Duncalf D, Novakovic M, Lesser ML. Common bile duct pressure changes after fentanyl, morphine, meperidine, butorphanol, and naloxone. Anesth Analg 1984; 63: 4.
Alderman EL, Barry WH, Graham AF, Harrison DC. Hemodynamic effects of morphine and pentazocine differ in cardiac patients. New Eng J Med 1972; 27: 623–7.
Popio KA, Jackson DH, Ross AM, Schreiner BF, Yu PN. Hemodynamic and respiratory effects of morphine and butorphanol. Clin Pharm Ther 1978; 23: 281–7.
Aldrete JA, de Campo T, Usubiaga LE, Renck R, Suzuki D, Witt WO. Comparison of butorphanol and morphine as analgesics for coronary bypass surgery: a double-blind, randomized study. Anesth Analg 1983; 62: 78–83.
Latasch L, Probst S, Dudziak R. Reversal by nalbuphine of respiratory depression caused by fentanyl. Anesth Analg 1984; 63: 814–6.
Preston KL, Bigelow GE, Liebson IA. Butorphanolprecipitated withdrawal in opioid-dependent human volunteers. J Pharm Exp Ther 1988; 246: 441–8.
Johanson CE, Yanagita T (Eds.). WHO Symposium on Drug Dependence: Benefit-Risk Ratio Assessment of Agonist-Antagonist Analgesics. Drug Alcohol Dep. 1987; 20: 289–409.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rosow, C. Agonist-antagonist opioids: theory and clinical practice. Can J Anaesth 36 (Suppl 1), S5–S8 (1989). https://doi.org/10.1007/BF03005319
Issue Date:
DOI: https://doi.org/10.1007/BF03005319